FORTITUDE-102
04 May 2022
Trial Summary
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression.
Acronym:
FORTITUDE-102
ACTRN/NCT /ethics:
NCT05111626
Scientific title:
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)
Sponsor / Cooperative group:
Amgen
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase III |
| Age Range | 18 years to 100 years |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2022-03-14 |
| Anticipated End Date | 2026-05-11 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Timothy Price |
| Recruitment Status | Recruiting |